Abstract
We treated ten children with severe IgA nephropathy (IgAN) [proteinuria > 1g/day, hypertension, renal insufficiency, segmental sclerosis, crescent formation and/or glomerular basement membrane (GBM) deposition of IgA] with prednisone and azathioprine for 1 year. Following the year of therapy, seven of the ten children underwent a repeat kidney biopsy. All biopsies were scored for activity (percentage of glomeruli demonstrating crescent formation, degree of mesangial proliferation and interstitial infiltrate; maximum score = 9) and chronicity (percentage of glomeruli demonstrating fibrous crescents, segmental sclerosis, global sclerosis, and degree of tubular atrophy and interstitial fibrosis; maximum score = 12). After 1 year of therapy, the protein excretion of all the children decreased significantly (P<0.01) from 4052±3190 mg/day to 1692±1634 mg/day. The activity score decreased significantly (P<0.01) from 4.35±0.94 prior to therapy to 2.28±0.75 after therapy while the chronicity score was unchanged (5.42±1.7 vs 5.85±2.0). The percentage of glomeruli demonstrating cellular crescents decreased (P<0.05) from 21.2±21.7% prior to therapy to 0.94±2.4% after therapy. Mesangial deposition of IgA persisted but GBM deposition of IgA was less prominent after therapy. During the follow-up period (mean 2.6 years, range 9 months–7.5 years), one child required brief retreatment for biopsy-confirmed recurrence of active disease, two children have developed renal insufficiency due to progressive scarring in the absence of inflammation, while the remaining seven are stable. We suggest that treatment with prednisone and azathioprine may be beneficial in children with severe IgAN and that a controlled clinical trial is warranted.
Similar content being viewed by others
References
Hood SA, Velosa JA, Holley KE, Donadio JV (1981) IgA-IgG nephropathy: predictive indices of progressive disease. Clin Nephrol 16:55–62
Lee SMK, Vijaykumar MR, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, Katz AI (1982) IgA nephropathy: morphological predictors of progressive renal disease. Hum Pathol 13:314–322
Wyatt RJ, Julian BA, Bhathena DB, Mitchell BL, Holland NH, Malluche HH (1984) IgA nephropathy: presentation, clinical course, and prognosis in children and adults. Am J Kidney Dis 4:192–200
Kobayashi Y, Tateno S, Hiki Y, Shigematsu H (1983) IgA nephropathy: prognostic significance of proteinuria and histologic alterations. Nephron 34:146–153
Katz A, Walker JF, Landy PJ (1983) IgA nephritis with nephrotic range proteinuria. Clin Nephrol 20:67–71
Levy M, Gonzalez-Burchard G, Broyer M, Dommergues JP, Foulard M, Sorez JP, Habib R (1985) Berger's disease in children: natural history and outcome. Medicine 64:157–180
Andreoli SP, Yum MN, Bergstein JM (1986) IgA Nephropathy in children: significance of glomerular basement membrane deposition of IgA. Am J Nephrol 6:28–33
D'Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, DiBelgioioso GB, Imbasciati E, Ragni A, Bertoli S, Fogazzi G, Duca G (1986) Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 228:363–378
Bennett WM, Kincaid-Smith P (1983) Macroscopic hematuria in mesangial IgA nephropathy: correlation with glomerular crescents and renal dysfunction. Kidney Int 23:393–440
Nicholls KM, Fairley KF, Dowling JP, Kincaid-Smith P (1984) The clinical course of mesangial IgA associated nephropathy in adults. Q J Med 210:227–250
Clarkson AR, Seymour AE, Woodroffe AJ, McKenzie PE, Chan YL, Wootton AM (1980) Controlled trial of phenytoin therapy in IgA nephropathy. Clin Nephrol 13:215–218
Egido J, Rivera F, Sancho J, Barat A, Hernando L (1984) Phenytoin in IgA nephropathy: a long-term controlled trial. Nephron 38:30–39
Chan MK, Kwan SYL, Chan KW, Yeung CK (1987) Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Am J Kidney Dis 9:417–421
Mustonen J, Pasternack A, Rantala I (1983) The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 20:172–176
Lai KN, Lai FM, Ho CP, Chan KW (1986) Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 26:174–180
Cameron JS (1983) Effect of the recipients disease on the results of transplantation. Kidney Int 23 [Suppl 14]:S24-S33
Mathew TH (1988) Recurrence of disease following renal transplantation. Am J Kidney Dis 12:85–96
Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE (1983) Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 75:382–391
Lai KN, Lai FMM, Chan KW, Ho CP, Leung ACT, Vallance-Owen J (1986) An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol 86:716–723
Southwest Pediatric Nephrology Study Group (1985) Association of IgA nephropathy with steroid-responsive nephrotic syndrome. Am J Kidney Dis 5:157–164
Kobayashi Y, Fujii K, Hiki Y, Tateno S (1986) Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med 234:935–943
Tomino Y, Sakai H, Miura M, Suga T, Endoh M, Nomoto Y (1984) Effect of danazol on solubilization of immune deposits in patients with IgA nephropathy. Am J Kidney Dis 4:135–140
Woo KT, Edmondson RPS, Yap HK, Wu AYT, Chiang GCS, Lee EJC, Pwee HS, Lim CH (1987) Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 27:56–64
Lai KN, Lai FMM, Li PKT, Vallance-Owen J (1987) Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J 295:1165–1168
Clarkson AR, Woodroffe AJ, Aarons I, Hiki Y, Hale G (1987) Annu Rev Med 38:157–168
Rodico JL (1984) Idiopathic IgA nephropathy. Kidney Int 25:717–729
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andreoli, S.P., Bergstein, J.M. Treatment of severe IgA nephropathy in children. Pediatr Nephrol 3, 248–253 (1989). https://doi.org/10.1007/BF00858524
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00858524